相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Aberrant maturation and connectivity of prefrontal cortex in schizophrenia-contribution of NMDA receptor development and hypofunction
Wen-Jun Gao et al.
MOLECULAR PSYCHIATRY (2022)
Not Just a Bystander: The Emerging Role of Astrocytes and Research Tools in Studying Cognitive Dysfunctions in Schizophrenia
Chia-Yuan Chang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Impairment of Executive Functions Associated With Lower D-Serine Serum Levels in Patients With Schizophrenia
Jaromir Hons et al.
FRONTIERS IN PSYCHIATRY (2021)
Comparative Pro-cognitive and Neurochemical Profiles of Glycine Modulatory Site Agonists and Glycine Reuptake Inhibitors in the Rat: Potential Relevance to Cognitive Dysfunction and Its Management
Kevin C. F. Fone et al.
MOLECULAR NEUROBIOLOGY (2020)
L-serine synthesis via the phosphorylated pathway in humans
Giulia Murtas et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2020)
D-Serine as the gatekeeper of NMDA receptor activity: implications for the pharmacologic management of anxiety disorders
Herman Wolosker et al.
TRANSLATIONAL PSYCHIATRY (2020)
Mechanistic Multilayer Quantitative Model for Nonlinear Pharmacokinetics, Target Occupancy and Pharmacodynamics (PK/TO/PD) Relationship of D-Amino Acid Oxidase Inhibitor, TAK-831 in Mice
Tomoki Yoneyama et al.
PHARMACEUTICAL RESEARCH (2020)
Effect of Sodium Benzoate vs Placebo Among Individuals With Early Psychosis A Randomized Clinical Trial
James G. Scott et al.
JAMA NETWORK OPEN (2020)
Trends in the incidence and DALYs of schizophrenia at the global, regional and national levels: results from the Global Burden of Disease Study 2017
Hairong He et al.
EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES (2020)
Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment
Christoph U. Correll et al.
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2020)
NMDA Receptor Model of Antipsychotic Drug-Induced Hypofrontality
Marek Krzystanek et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Targeted Treatment of Individuals With Psychosis Carrying a Copy Number Variant Containing a Genomic Triplication of the Glycine Decarboxylase Gene
J. Alexander Bodkin et al.
BIOLOGICAL PSYCHIATRY (2019)
D-Serine: Potential Therapeutic Agent and/or Biomarker in Schizophrenia and Depression?
Mary-Anne B. MacKay et al.
FRONTIERS IN PSYCHIATRY (2019)
Therapeutic potential and underlying mechanism of sarcosine (N-methylglycine) in N-methyl-D-aspartate (NMDA) receptor hypofunction models of schizophrenia
Ju-Chun Pei et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2019)
Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities
Amanda Krogmann et al.
CNS SPECTRUMS (2019)
The impact of D-cycloserine and sarcosine on in vivo frontal neural activity in a schizophrenia-like model
Lulu Yao et al.
BMC PSYCHIATRY (2019)
Investigating brain d-serine: Advocacy for good practices
Jean-Pierre Mothet et al.
ACTA PHYSIOLOGICA (2019)
Serum D-serine accumulation after proximal renal tubular damage involves neutral amino acid transporter Asc-1
Masataka Suzuki et al.
SCIENTIFIC REPORTS (2019)
Glutamate hypothesis in schizophrenia
Yota Uno et al.
PSYCHIATRY AND CLINICAL NEUROSCIENCES (2019)
Association study of the excitatory amino acid transporter 2 (EAAT2) and glycine transporter 1 (GlyT1) gene polymorphism with schizophrenia in a Polish population
Wojciech Merk et al.
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2019)
Safety, Tolerability and Pharmacokinetics of Oral BI 425809, a Glycine Transporter 1 Inhibitor, in Healthy Male Volunteers: A Partially Randomised, Single-Blind, Placebo-Controlled, First-in-Human Study
Viktoria Moschetti et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2018)
A systematic meta-analysis of the association of Neuregulin 1 (NRG1), D-amino acid oxidase (DAO), and DAO activator (DAOA)/G72 polymorphisms with schizophrenia
Vinita Jagannath et al.
JOURNAL OF NEURAL TRANSMISSION (2018)
Dose-Related Target Occupancy and Effects on Circuitry, Behavior, and Neuroplasticity of the Glycine Transporter-1 Inhibitor PF-03463275 in Healthy and Schizophrenia Subjects
Deepak Cyril D'Souza et al.
BIOLOGICAL PSYCHIATRY (2018)
Multiple Rising Doses of Oral BI 425809, a GlyT1 Inhibitor, in Young and Elderly Healthy Volunteers: A Randomised, Double-Blind, Phase I Study Investigating Safety and Pharmacokinetics
Viktoria Moschetti et al.
CLINICAL DRUG INVESTIGATION (2018)
Glycine transporter-1 inhibitors: a patent review (2011-2016)
Christopher L. Cioffi
EXPERT OPINION ON THERAPEUTIC PATENTS (2018)
Serum levels of interleukin 6 in schizophrenic patients during treatment augmentation with sarcosine (results of the PULSAR study)
Dominik Strzelecki et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2018)
NGL-2 Deletion Leads to Autistic-like Behaviors Responsive to NMDAR Modulation
Seung Min Um et al.
CELL REPORTS (2018)
Cognitive Deficits in Schizophrenia: Understanding the Biological Correlates and Remediation Strategies
Adarsh Tripathi et al.
CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE (2018)
Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial
Chieh-Hsin Lin et al.
BIOLOGICAL PSYCHIATRY (2018)
Evaluation of Pharmacokinetics and Pharmacodynamics of BI 425809, a Novel GlyT1 Inhibitor: Translational Studies
Holger Rosenbrock et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2018)
Serum levels of TNF-alpha in patients with chronic schizophrenia during treatment augmentation with sarcosine (results of the PULSAR study)
Dominik Strzelecki et al.
PSYCHIATRY RESEARCH (2018)
The effects of glycine on auditory mismatch negativity in schizophrenia
Lisa-Marie Greenwood et al.
SCHIZOPHRENIA RESEARCH (2018)
Improvement in mismatch negativity generation during D-serine treatment in schizophrenia: Correlation with symptoms
Joshua T. Kantrowitz et al.
SCHIZOPHRENIA RESEARCH (2018)
Inhibition of glial glutamate transporter GLT1 in the nucleus of the solitary tract attenuates baroreflex control of sympathetic nerve activity and heart rate
Kenta Yamamoto et al.
PHYSIOLOGICAL REPORTS (2018)
Biochemical Properties of Human D-amino Acid Oxidase Variants and Their Potential Significance in Pathologies
Silvia Sacchi et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2018)
D-Amino Acid Oxidase-pLG72 Interaction and D-Serine Modulation
Loredano Pollegioni et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2018)
Glycinamide, a Glycine Precursor, Caught in the Gas Phase: A Laser-ablation Jet-cooled Rotational Study
E. R. Alonso et al.
ASTROPHYSICAL JOURNAL (2018)
Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial
Chun-Yuan Lin et al.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2017)
Neurophysiological Effects of Bitopertin in Schizophrenia
Joshua T. Kantrowitz et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2017)
Effects of Augmenting N-Methyl-D-Aspartate Receptor Signaling on Working Memory and Experience-Dependent Plasticity in Schizophrenia: An Exploratory Study Using Acute D-cycloserine
Jennifer K. Forsyth et al.
SCHIZOPHRENIA BULLETIN (2017)
Efficacy and safety of the glycine transporter type-1 inhibitor AMG 747 for the treatment of negative symptoms associated with schizophrenia
Eduardo Dunayevich et al.
SCHIZOPHRENIA RESEARCH (2017)
Astroglial versus Neuronal D-Serine: Fact Checking
Thomas Papouin et al.
TRENDS IN NEUROSCIENCES (2017)
The efficacy of sodium benzoate as an adjunctive treatment in early psychosis - CADENCE-BZ: study protocol for a randomized controlled trial
Alex Ryan et al.
TRIALS (2017)
Prediction analysis for Transition to schizophrenia in individuals at clinical high risk for Psychosis: The relationship of DAO, DAOA, and NRG1 Variants with negative symptoms and cognitive Deficits
Vinita Jagannath et al.
FRONTIERS IN PSYCHIATRY (2017)
Biochemical Properties of Human D-Amino Acid Oxidase
Giulia Murtas et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2017)
Competitive Inhibitors Unveil Structure/Function Relationships in Human D-Amino Acid Oxidase
Gianluca Molla
FRONTIERS IN MOLECULAR BIOSCIENCES (2017)
Association of schizophrenia onset age and white matter integrity with treatment effect of D-cycloserine: a randomized placebo-controlled double-blind crossover study
Kazuo Takiguchi et al.
BMC PSYCHIATRY (2017)
Bitopertin in Negative Symptoms of Schizophrenia-Results From the Phase III FlashLyte and DayLyte Studies
Dragana Bugarski-Kirola et al.
BIOLOGICAL PSYCHIATRY (2017)
Neuropsychiatric Effects of Antimicrobial Agents
Nicholas Zareifopoulos et al.
CLINICAL DRUG INVESTIGATION (2017)
Health-related quality of life in patients with prominent negative symptoms: results from a multicenter randomized Phase II trial on bitopertin
Diana Rofail et al.
QUALITY OF LIFE RESEARCH (2016)
A quantitative review of the postmortem evidence for decreased cortical N-methyl-D-aspartate receptor expression levels in schizophrenia: How can we link molecular abnormalities to mismatch negativity deficits?
Vibeke S. Catts et al.
BIOLOGICAL PSYCHOLOGY (2016)
A double-blind randomized study assessing safety and efficacy following one-year adjunctive treatment with bitopertin, a glycine reuptake inhibitor, in Japanese patients with schizophrenia
Yoshio Hirayasu et al.
BMC PSYCHIATRY (2016)
Neurophysiological mechanisms of cortical plasticity impairments in schizophrenia and modulation by the NMDA receptor agonist D-serine
Joshua T. Kantrowitz et al.
BRAIN (2016)
Low D-serine levels in schizophrenia: A systematic review and meta-analysis
Seo-Eun Cho et al.
NEUROSCIENCE LETTERS (2016)
BDNF serum levels in schizophrenic patients during treatment augmentation with sarcosine (results of the PULSAR study)
Dominik Strzelecki et al.
PSYCHIATRY RESEARCH (2016)
The Rise and Fall of the D-Serine-Mediated Gliotransmission Hypothesis
Herman Wolosker et al.
TRENDS IN NEUROSCIENCES (2016)
Supplementation with D-serine prevents the onset of cognitive deficits in adult offspring after maternal immune activation
Yuko Fujita et al.
SCIENTIFIC REPORTS (2016)
Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme
Dragana Bugarski-Kirola et al.
LANCET PSYCHIATRY (2016)
MMP-9 Serum Levels in Schizophrenic Patients during Treatment Augmentation with Sarcosine (Results of the PULSAR Study)
Dominik Strzelecki et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Effects of sodium benzoate on pre-pulse inhibition deficits and hyperlocomotion in mice after administration of phencyclidine
Akiko Matsuura et al.
ACTA NEUROPSYCHIATRICA (2015)
Clinical and Electrophysiological Effects of D-Serine in a Schizophrenia Patient Positive for Anti-N-Methyl- D-Aspartate Receptor Antibodies
Uriel Heresco-Levy et al.
BIOLOGICAL PSYCHIATRY (2015)
Antipsychotic medication in schizophrenia: a review
John Lally et al.
BRITISH MEDICAL BULLETIN (2015)
The NMDA receptor 'glycine modulatory site' in schizophrenia: D-serine, glycine, and beyond
Darrick T. Balu et al.
CURRENT OPINION IN PHARMACOLOGY (2015)
Inhibition of Glycine Transporter 1: The Yellow Brick Road to New Schizophrenia Therapy?
Philipp Singer et al.
CURRENT PHARMACEUTICAL DESIGN (2015)
Adding Sarcosine to Antipsychotic Treatment in Patients with Stable Schizophrenia Changes the Concentrations of Neuronal and Glial Metabolites in the Left Dorsolateral Prefrontal Cortex
Dominik Strzelecki et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)
Time and space profiling of NMDA receptor co-agonist functions
Jean-Pierre Mothet et al.
JOURNAL OF NEUROCHEMISTRY (2015)
No changes of cardiometabolic and body composition parameters after 6-month add-on treatment with sarcosine in patients with schizophrenia
Dominik Strzelecki et al.
PSYCHIATRY RESEARCH (2015)
Latent structure of cognition in schizophrenia: a confirmatory factor analysis of the MATRICS Consensus Cognitive Battery (MCCB)
A. McCleery et al.
PSYCHOLOGICAL MEDICINE (2015)
The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia
Samuel M. Cohen et al.
SCHIZOPHRENIA RESEARCH (2015)
Supplementation of Antipsychotic Treatment with the Amino Acid Sarcosine Influences Proton Magnetic Resonance Spectroscopy Parameters in Left Frontal White Matter in Patients with Schizophrenia
Dominik Strzelecki et al.
NUTRIENTS (2015)
Effects of sodium benzoate on pre-pulse inhibition deficits and hyperlocomotion in mice after administration of phencyclidine
Akiko Matsuura et al.
ACTA NEUROPSYCHIATRICA (2015)
Src kinase as a mediator of convergent molecular abnormalities leading to NMDAR hypoactivity in schizophrenia
A. Banerjee et al.
MOLECULAR PSYCHIATRY (2015)
D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial
Joshua T. Kantrowitz et al.
LANCET PSYCHIATRY (2015)
Hypomania after augmenting venlafaxine and olanzapine with sarcosine in a patient with schizophrenia: a case study
Dominik Strzelecki et al.
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2015)
Clozapine and glycinamide prevent MK-801-induced deficits in the novel object recognition (NOR) test in the domestic rabbit (Oryctolagus cuniculus)
Kurt L. Hoffman et al.
BEHAVIOURAL BRAIN RESEARCH (2014)
Novel human D-amino acid oxidase inhibitors stabilize an active-site id-open conformation
Ryan T. Terry-Lorenzo et al.
BIOSCIENCE REPORTS (2014)
A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia - Results from the CandleLyte study
D. Bugarski-Kirola et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2014)
The Selective Glycine Uptake Inhibitor Org 25935 as an Adjunctive Treatment to Atypical Antipsychotics in Predominant Persistent Negative Symptoms of Schizophrenia Results From the GIANT Trial
Joep H. Schoemaker et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2014)
Distinctively higher plasma G72 protein levels in patients with schizophrenia than in healthy individuals
C-H Lin et al.
MOLECULAR PSYCHIATRY (2014)
SEARCHING FOR SCHIZ OPHRENIA'S ROOTS
Emily Elert
NATURE (2014)
De novo mutations in schizophrenia implicate synaptic networks
Menachem Fromer et al.
NATURE (2014)
Biological insights from 108 schizophrenia-associated genetic loci
Stephan Ripke et al.
NATURE (2014)
Reliability, validity and ability to detect change of the PANSS negative symptom factor score in outpatients with schizophrenia on select antipsychotics and with prominent negative or disorganized thought symptoms
Chris J. Edgar et al.
PSYCHIATRY RESEARCH (2014)
The relationship between glycine transporter 1 occupancy and the effects of the glycine transporter 1 inhibitor RG1678 or ORG25935 on object retrieval performance in scopolamine impaired rhesus monkey
Donnie Eddins et al.
PSYCHOPHARMACOLOGY (2014)
D-Cycloserine augmentation of cognitive remediation in schizophrenia
Christopher K. Cain et al.
SCHIZOPHRENIA RESEARCH (2014)
Efficacy and safety of adjunctive bitopertin (5 and 10mg) versus placebo in subjects with persistent predominant negative symptoms of schizophrenia treated with antipsychotics — Results from the phase III DayLyte study
Celso Arango et al.
SCHIZOPHRENIA RESEARCH (2014)
Efficacy and safety of adjunctive bitopertin (10 and 20mg) versus placebo in subjects with persistent predominant negative symptoms of schizophrenia treated with antipsychotics — Results from the Phase III FlashLyte Study
Thomas Blaettler et al.
SCHIZOPHRENIA RESEARCH (2014)
Two grams of sarcosine in schizophrenia - is it too much? A potential role of glutamate-serotonin interaction
Dominik Strzelecki et al.
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2014)
Effect of Bitopertin, a Glycine Reuptake Inhibitor, on Negative Symptoms of Schizophrenia A Randomized, Double-Blind, Proof-of-Concept Study
Daniel Umbricht et al.
JAMA PSYCHIATRY (2014)
Structural, Kinetic, and Pharmacodynarnic Mechanisms of D-Amino Acid Oxidase Inhibition by Small Molecules
Seth C. Hopkins et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Neuronal D-Serine and Glycine Release Via the Asc-1 Transporter Regulates NMDA Receptor-Dependent Synaptic Activity
Dina Rosenberg et al.
JOURNAL OF NEUROSCIENCE (2013)
Deconstructing negative symptoms of schizophrenia: Avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome
Gregory P. Strauss et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2013)
Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia
C. S. Weickert et al.
MOLECULAR PSYCHIATRY (2013)
Feasibility, Safety, and Efficacy of the Combination of D-Serine and Computerized Cognitive Retraining in Schizophrenia: An International Collaborative Pilot Study
Deepak C. D'Souza et al.
NEUROPSYCHOPHARMACOLOGY (2013)
Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction
Darrick T. Balu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
A pilot double-blind comparison of D-serine and high-dose olanzapine in treatment-resistant patients with schizophrenia
Marina Ermilov et al.
SCHIZOPHRENIA RESEARCH (2013)
Clinical symptoms, mainly negative symptoms, mediate the influence of neurocognition and social cognition on functional outcome of schizophrenia
Chieh-Hsin Lin et al.
SCHIZOPHRENIA RESEARCH (2013)
Identity of endogenous NMDAR glycine site agonist in amygdala is determined by synaptic activity level
Yan Li et al.
NATURE COMMUNICATIONS (2013)
Add-on Treatment of Benzoate for Schizophrenia A Randomized, Double-blind, Placebo-Controlled Trial of D-Amino Acid Oxidase Inhibitor
Hsien-Yuan Lane et al.
JAMA PSYCHIATRY (2013)
Structure-function relationships in human d-amino acid oxidase
Silvia Sacchi et al.
AMINO ACIDS (2012)
Synaptic and Extrasynaptic NMDA Receptors Are Gated by Different Endogenous Coagonists
Thomas Papouin et al.
CELL (2012)
Cell Selective Conditional Null Mutations of Serine Racemase Demonstrate a Predominate Localization in Cortical Glutamatergic Neurons
Michael A. Benneyworth et al.
CELLULAR AND MOLECULAR NEUROBIOLOGY (2012)
The Glutamate Hypothesis of Schizophrenia: Neuroimaging and Drug Development
Alice Egerton et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2012)
A Multicenter, Add-On Randomized Controlled Trial of Low-Dosed-Serine for Negative and Cognitive Symptoms of Schizophrenia
Mark Weiser et al.
JOURNAL OF CLINICAL PSYCHIATRY (2012)
De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia
G. Kirov et al.
MOLECULAR PSYCHIATRY (2012)
Kynurenines in the mammalian brain: when physiology meets pathology
Robert Schwarcz et al.
NATURE REVIEWS NEUROSCIENCE (2012)
GABAergic interneuron origin of schizophrenia pathophysiology
Kazu Nakazawa et al.
NEUROPHARMACOLOGY (2012)
Glycine reuptake inhibitor RG1678: A pharmacologic characterization of an investigational agent for the treatment of schizophrenia
Daniela Alberati et al.
NEUROPHARMACOLOGY (2012)
From Revolution to Evolution: The Glutamate Hypothesis of Schizophrenia and its Implication for Treatment
Bita Moghaddam et al.
NEUROPSYCHOPHARMACOLOGY (2012)
NMDA Receptor Hypofunction, Parvalbumin-Positive Neurons, and Cortical Gamma Oscillations in Schizophrenia
Guillermo Gonzalez-Burgos et al.
SCHIZOPHRENIA BULLETIN (2012)
Serine racemase and the serine shuttle between neurons and astrocytes
Herman Wolosker
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2011)
First-Time-in-Human Study With GSK1018921, a Selective GlyT1 Inhibitor: Relationship Between Exposure and Dizziness
D. Ouellet et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
High-dose glycine impairs the prepulse inhibition measure of sensorimotor gating in humans
B. V. O'Neill et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2011)
D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia
Jennifer D. Gottlieb et al.
SCHIZOPHRENIA RESEARCH (2011)
SSR504734, a glycine transporter-1 inhibitor, attenuates acquisition and expression of contextual conditioned fear in rats
Hiroyuki Nishikawa et al.
BEHAVIOURAL PHARMACOLOGY (2010)
Glycine transporter (GlyT1) inhibitors with reduced residence time increase prepulse inhibition without inducing hyperlocomotion in DBA/2 mice
Karla Kopec et al.
BIOCHEMICAL PHARMACOLOGY (2010)
Strategies to Enhance N-Methyl-D-Aspartate Receptor-Mediated Neurotransmission in Schizophrenia, a Critical Review and Meta-Analysis
Guochuan E. Tsai et al.
CURRENT PHARMACEUTICAL DESIGN (2010)
A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia
Hsien-Yuan Lane et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2010)
The effect of risperidone on D-amino acid oxidase activity as a hypothesis for a novel mechanism of action in the treatment of schizophrenia
R. M. Abou El-Magd et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2010)
The neurobiology of D-amino acid oxidase and its involvement in schizophrenia
L. Verrall et al.
MOLECULAR PSYCHIATRY (2010)
Effect of ligand binding on human D-amino acid oxidase: Implications for the development of new drugs for schizophrenia treatment
Laura Caldinelli et al.
PROTEIN SCIENCE (2010)
The glutamatergic compounds sarcosine and N-acetylcysteine ameliorate prepulse inhibition deficits in metabotropic glutamate 5 receptor knockout mice
Hwei-Hsien Chen et al.
PSYCHOPHARMACOLOGY (2010)
d-Serine and a glycine transporter-1 inhibitor enhance social memory in rats
Toshiharu Shimazaki et al.
PSYCHOPHARMACOLOGY (2010)
High dose D-serine in the treatment of schizophrenia
Joshua T. Kantrowitz et al.
SCHIZOPHRENIA RESEARCH (2010)
Identification of an Orally Bioavailable, Potent, and Selective Inhibitor of GlyT1
Wesley P. Blackaby et al.
ACS MEDICINAL CHEMISTRY LETTERS (2010)
Co-Administration of a D-Amino Acid Oxidase Inhibitor Potentiates the Efficacy of D-Serine in Attenuating Prepulse Inhibition Deficits After Administration of Dizocilpine
Kenji Hashimoto et al.
BIOLOGICAL PSYCHIATRY (2009)
The discovery of a structurally novel class of inhibitors of the type 1 glycine transporter
John A. Lowe et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
D-Serine induces lipid and protein oxidative damage and decreases glutathione levels in brain cortex of rats
Lucila de Bortoli da Silva et al.
BRAIN RESEARCH (2009)
Schizophrenia from a neural circuitry perspective: advancing toward rational pharmacological therapies
David A. Lewis et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Comparative virtual screening and novelty detection for NMDA-GlycineB antagonists
Bjoern A. Krueger et al.
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN (2009)
Discovery, SAR, and Pharmacokinetics of a Novel 3-Hydroxyquinolin-2(1H)-one Series of Potent D-Amino Acid Oxidase (DAAO) Inhibitors
Allen J. Duplantier et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
The Behavioral and Neurochemical Effects of a Novel D-Amino Acid Oxidase Inhibitor Compound 8 [4H-Thieno [3,2-b]pyrrole-5-carboxylic Acid] and D-Serine
Sean M. Smith et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
The glycine transport inhibitor sarcosine is an NMDA receptor co-agonist that differs from glycine
Hai Xia Zhang et al.
JOURNAL OF PHYSIOLOGY-LONDON (2009)
Augmentation of Fear Extinction by Infusion of Glycine Transporter Blockers into the Amygdala
Sheng-Chun Mao et al.
MOLECULAR PHARMACOLOGY (2009)
Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior
A. C. Basu et al.
MOLECULAR PSYCHIATRY (2009)
A putative high risk diplotype of the G72 gene is in healthy individuals associated with better performance in working memory functions and altered brain activity in the medial temporal lobe
Andreas Jansen et al.
NEUROIMAGE (2009)
Relevance of weak flavin binding in human D-amino acid oxidase
Laura Caldinelli et al.
PROTEIN SCIENCE (2009)
The glycine transporter 1 inhibitor SSR504734 enhances working memory performance in a continuous delayed alternation task in C57BL/6 mice
Philipp Singer et al.
PSYCHOPHARMACOLOGY (2009)
D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats
Jun-Ichi Karasawa et al.
BEHAVIOURAL BRAIN RESEARCH (2008)
Sarcosine (N-Methylglycine) treatment for acute schizophrenia: A randomized, double-blind study
Hsien-Yuan Lane et al.
BIOLOGICAL PSYCHIATRY (2008)
Genetic variation in the DAOA (G72) gene modulates hippocampal function in subjects at high risk of schizophrenia
Jeremy Hall et al.
BIOLOGICAL PSYCHIATRY (2008)
Rescue of hippocampal LTP and learning deficits in a rat model of psychosis by inhibition of glycine transporter-1 (GlyT1)
Denise Manahan-Vaughan et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2008)
Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the glycine transporter-1 inhibitor NFPS and D-serine
Kenji Hashimoto et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2008)
In vitro and in vivo pharmacological profile of AS057278, a selective D-amino acid oxidase inhibitor with potential anti-psychotic properties
Tiziana Adage et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2008)
Glycine Transporters and Synaptic Function
Francisco Zafra et al.
IUBMB LIFE (2008)
pLG72 modulates intracellular D-serine levels through its interaction with D-amino acid oxidase - Effect on schizophrenia susceptibility
Silvia Sacchi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Serine racemase is predominantly localized in neurons in mouse brain
Kazushi Miya et al.
JOURNAL OF COMPARATIVE NEUROLOGY (2008)
Chlorpromazine oligomer is a potentially active substance that inhibits human D-amino acid oxidase, product of a susceptibility gene for schizophrenia
Sanae Iwana et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2008)
Synthesis and biological evaluation of D-amino acid oxidase inhibitors
Dana Ferraris et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
D-amino acid oxidase activity and expression are increased in schizophrenia
P. W. J. Burnet et al.
MOLECULAR PSYCHIATRY (2008)
Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database
Nicole C. Allen et al.
NATURE GENETICS (2008)
Neurophysiological biomarkers for drug development in schizophrenia
Daniel C. Javitt et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia
Denis Boulay et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2008)
Glycine and D-serine, but not D-cycloserine, attenuate prepulse inhibition deficits induced by NMDA receptor antagonist MK-801
Nobuhisa Kanahara et al.
PSYCHOPHARMACOLOGY (2008)
Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia
Viviane Labrie et al.
PSYCHOPHARMACOLOGY (2008)
Genetic variation in the DAOA gene complex: Impact on susceptibility for schizophrenia and on cognitive performance
Carolin Opgen-Rhein et al.
SCHIZOPHRENIA RESEARCH (2008)
Increased brain D-amino acid oxidase (DAAO) activity in schizophrenia
Caroline Madeira et al.
SCHIZOPHRENIA RESEARCH (2008)
Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: An exploratory study
Donald C. Goff et al.
SCHIZOPHRENIA RESEARCH (2008)
Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia
John E. Lisman et al.
TRENDS IN NEUROSCIENCES (2008)
The Cognitive and Negative Symptoms in Schizophrenia, Trial (CONSIST): The efficacy of glutamatergic agents for negative symptoms and cognitive impairments
Robert W. Buchanan et al.
AMERICAN JOURNAL OF PSYCHIATRY (2007)
D-Amino acid oxidase and serine racemase in human brain: normal distribution and altered expression in schizophrenia
Louise Verrall et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2007)
Involvement of a dysfunctional dopamine-D1/N-methyl-D-aspartate-NR1 and Ca2+/calmodulin-dependent protein kinase II pathway in the impairment of latent learning in a model of schizophrenia induced by phencyclidine
Akihiro Mouri et al.
MOLECULAR PHARMACOLOGY (2007)
High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients
Uriel Heresco-Levy et al.
SCHIZOPHRENIA RESEARCH (2007)
A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia
Inna Bendikov et al.
SCHIZOPHRENIA RESEARCH (2007)
Crystal structure of human D-amino acid oxidase:: Context-dependent variability of the backbone conformation of the VAAGL hydrophobic stretch located at the si-face of the flavin ring
Tomoya Kawazoe et al.
PROTEIN SCIENCE (2006)
Association study of polymorphisms in glycine transporter with schizophrenia
S. -J. Tsai et al.
JOURNAL OF NEURAL TRANSMISSION (2006)
Glycine transporter I inhibitor, N-methylglycine (Sarcosine), added to clozapine for the treatment of schizophrenia
Hsien-Yuan Lane et al.
BIOLOGICAL PSYCHIATRY (2006)
Behavioral and biochemical characterization of a mutant mouse strain lacking D-amino acid oxidase activity and its implications for schizophrenia
S. L. Almond et al.
MOLECULAR AND CELLULAR NEUROSCIENCE (2006)
Schizophrenia-relevant behavioral testing in rodent models: A uniquely human disorder?
Craig M. Powell et al.
BIOLOGICAL PSYCHIATRY (2006)
Neuron-derived D-serine release provides a novel means to activate N-methyl-D-aspartate receptors
Elena Kartvelishvily et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Characterization of human D-amino acid oxidase
G Molla et al.
FEBS LETTERS (2006)
Disruption of glycine transporter 1 restricted to forebrain neurons is associated with a procognitive and antipsychotic phenotypic profile
BK Yee et al.
JOURNAL OF NEUROSCIENCE (2006)
Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists
KW Muir
CURRENT OPINION IN PHARMACOLOGY (2006)
D-Amino-acid oxidase is involved in D-serine-induced nephrotoxicity
M Maekawa et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2005)
Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia - A randomized, double-blind, placebo-controlled study
HY Lane et al.
ARCHIVES OF GENERAL PSYCHIATRY (2005)
Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-I SSR504734, a potential new type of antipsychotic
R Depoortère et al.
NEUROPSYCHOPHARMACOLOGY (2005)
D-serine is the dominant endogenous coagonist for NMDA receptor neurotoxicity in organotypic hippocampal slices
M Shleper et al.
JOURNAL OF NEUROSCIENCE (2005)
Spatial learning and long-term potentiation of mutant mice lacking D-amino-acid oxidase
M Maekawa et al.
NEUROSCIENCE RESEARCH (2005)
Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type
G Neeman et al.
AMERICAN JOURNAL OF PSYCHIATRY (2005)
Double-blind, placebo-controlled, crossover trial of clozapine plus glycine in refractory schizophrenia negative results
P Diaz et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2005)
Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia
T Lipina et al.
PSYCHOPHARMACOLOGY (2005)
Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects
JH Krystal et al.
PSYCHOPHARMACOLOGY (2005)
A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients
DC Goff et al.
PSYCHOPHARMACOLOGY (2005)
D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia
U Heresco-Levy et al.
BIOLOGICAL PSYCHIATRY (2005)
Sodium benzoate attenuates D-serine induced nephrotoxicity in the rat
RE Williams et al.
TOXICOLOGY (2005)
Functional magnetic resonance imaging studies of schizophrenic patients during word production: effects of D-cycloserine
DA Yurgelun-Todd et al.
PSYCHIATRY RESEARCH-NEUROIMAGING (2005)
Enhancement of the NMDA receptor function by reduction of glycine transporter-1 expression
L Gabernet et al.
NEUROSCIENCE LETTERS (2005)
Glycine transporter I inhibitor, N-methylglycine (Sarcosine), added to antipsychotics for the treatment of schizophrenia
GC Tsai et al.
BIOLOGICAL PSYCHIATRY (2004)
Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis
U Heresco-Levy et al.
SCHIZOPHRENIA RESEARCH (2004)
High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia
U Heresco-Levy et al.
BIOLOGICAL PSYCHIATRY (2004)
Is the G72/G30 locus associated with schizophrenia? Single nucleotide polymorphisms, haplotypes, and gene expression analysis
M Korostishevsky et al.
BIOLOGICAL PSYCHIATRY (2004)
Effects of D-cycloserine on negative symptoms in schizophrenia
EJ Duncan et al.
SCHIZOPHRENIA RESEARCH (2004)
Gene knockout of glycine transporter 1: Characterization of the behavioral phenotype
G Tsai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Endogenous D-serine is involved in induction of neuronal death by N-methyl-D-aspartate and simulated ischemia in rat cerebrocortical slices
H Katsuki et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Decreased serum levels of D-serine in patients with schizophrenia - Evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia
K Hashimoto et al.
ARCHIVES OF GENERAL PSYCHIATRY (2003)
Effects of D-cycloserine on extinction of conditioned freezing
L Ledgerwood et al.
BEHAVIORAL NEUROSCIENCE (2003)
Prepulse inhibition deficits of the startle reflex in neonatal ventral hippocampal-lesioned rats: Reversal by glycine and a glycine transporter inhibitor
G Le Pen et al.
BIOLOGICAL PSYCHIATRY (2003)
Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers
J Théberge et al.
AMERICAN JOURNAL OF PSYCHIATRY (2002)
Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia
I Chumakov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
D-cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia
AE Evins et al.
SCHIZOPHRENIA RESEARCH (2002)
Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats
DL Walker et al.
JOURNAL OF NEUROSCIENCE (2002)
Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia
U Heresco-Levy et al.
AMERICAN JOURNAL OF PSYCHIATRY (2002)
Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia
S Erhardt et al.
NEUROSCIENCE LETTERS (2001)
NMDA receptor subunits: diversity, development and disease
S Cull-Candy et al.
CURRENT OPINION IN NEUROBIOLOGY (2001)
Chronic high-dose glycine nutrition: Effects on rat brain cell morphology
S Shoham et al.
BIOLOGICAL PSYCHIATRY (2001)
Glycine reduces novelty- and methamphetamine-induced locomotor activity in neonatal ventral hippocampal damaged rats
K Kato et al.
NEUROPSYCHOPHARMACOLOGY (2001)
Systematic screening for mutations in the glycine receptor α2 subunit gene (GLRA2) in patients with schizophrenia and other psychiatric diseases
J Feng et al.
PSYCHIATRIC GENETICS (2001)
Imaging the glutamatergic system in vivo -: relevance to schizophrenia
RA Bressan et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE (2000)
Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: Implications for schizophrenia
LS Kegeles et al.
BIOLOGICAL PSYCHIATRY (2000)
Placebo-controlled trial of glycine added to clozapine in schizophrenia
AE Evins et al.
AMERICAN JOURNAL OF PSYCHIATRY (2000)
分享论文
